Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicenter, multicohort, single-arm phase 2 trial

Younes, A; Santoro, A; Shipp, M; Zinzani, P L; Timmerman, J M; Ansell, S; Armand, P; Fanale, M; Ratanatharathorn, V; Kuruvilla, J; Cohen, J B; Collins, G; Savage, K J; Trneny, M; Kato, K; Farsaci, B; Parker, S M; Rodig, S; Roemer, M G M; Ligon, A H